Non-Small-cell lung cancer intracranial metastases

Lung cancer is the leading cause of cancer mortality worldwide, accounting for 1.38 million annual deaths, representing 18.2% of total deaths from cancer 1).

Among those, approximately 7.4% of non-Small-cell lung cancer (NSCLC) patients will have brain metastases (BM) at presentation 2) , and between 20–40% of Non-Small-cell lung cancer (NSCLC) patients will develop intracranial metastases 3) 4).

see also Anaplastic lymphoma kinase non-Small-cell lung cancer intracranial metastases

see Non-Small-cell lung cancer intracranial metastases treatment.

see Non-Small-cell lung cancer intracranial metastases outcome.

see Non Small-cell lung cancer intracranial metastases case series.

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. doi: 10.3322/caac.20107. Epub 2011 Feb 4. Erratum in: CA Cancer J Clin. 2011 Mar-Apr;61(2):134. PubMed PMID: 21296855.
Schuette W. Treatment of brain metastases from lung cancer: chemotherapy. Lung Cancer. 2004 Aug;45 Suppl 2:S253-7. Review. PubMed PMID: 15552807.
Brower JV, Robins HI. Erlotinib for the treatment of brain metastases in non-Small-cell lung cancer. Expert Opin Pharmacother. 2016;17(7):1013-21. doi: 10.1517/14656566.2016.1165206. Epub 2016 Mar 30. Review. PubMed PMID: 26967582.
Zhao J, Chen M, Zhong W, Zhang L, Li L, Xiao Y, Nie L, Hu P, Wang M. Cerebrospinal fluid concentrations of gefitinib in patients with lung adenocarcinoma. Clin Lung Cancer. 2013 Mar;14(2):188-93. doi: 10.1016/j.cllc.2012.06.004. Epub 2012 Jul 28. PubMed PMID: 22846582.
  • non-small-cell_lung_cancer_intracranial_metastases.txt
  • Last modified: 2021/06/21 12:01
  • by administrador